FDA Notice: These stem cell therapies have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). Stem cell therapy is not intended to diagnose, treat, cure, or prevent any disease. All stem cell procedures at Rebuild Regen Medical Clinic are performed under the supervision of our Medical Director, [MD_PLACEHOLDER] MD, in compliance with Florida SB 1768. Learn about Florida stem cell law and SB 1768 compliance.

Stem Cell Therapy: The Complete 2025 Guide — 9 Key Questions, SB 1768 Compliance, and the DayZero™ Protocol

Table of Contents

What Umbilical Cord Stem Cell Therapy Is
How Mesenchymal Stem Cells Work: The Signaling Mechanism
Types of Stem Cell Therapy: Allogeneic vs. BMAC and Other Autologous Options
Conditions Addressed With Stem Cell Therapy
Who Is a Candidate for Stem Cell Therapy
What to Expect: Before, During, and After Your Procedure
Results and Realistic Expectations
Costs: What DayZero™ Protocols Include
The Rebuild Regen Approach: DayZero™ Sourcing, Vial Options, and Physician Oversight
Regulatory Context: SB 1768 Compliance and FDA Status
Is Stem Cell Therapy Right for Your Condition?
Frequently Asked Questions
When Stem Cell Therapy Is Not Appropriate

What Umbilical Cord Stem Cell Therapy Is

Umbilical cord stem cell therapy is a physician-supervised regenerative procedure that introduces allogeneic mesenchymal stem cells derived from perinatal tissue into the body to modulate inflammation, recruit tissue repair signals, and support recovery across orthopedic, neurological, and systemic conditions.

The term "stem cell therapy" covers a broad range of procedures, and the distinction between source types matters clinically. Umbilical cord-derived stem cell therapy specifically uses mesenchymal stem cells (MSCs) collected from the Wharton's jelly of donated umbilical cords after healthy, full-term births. The donors are screened, the tissue is processed in an FDA-registered cGMP facility, and every lot carries a Certificate of Analysis (COA) confirming cell viability, sterility, and absence of pathogens.

At Rebuild Regen Medical Clinic, the biologics used are exclusively from ZEO ScientifiX's DayZero™ line. DayZero™ umbilical cord stem cells are AABB-accredited, cGMP-manufactured in an ISO-7 Clean Room, and registered with the FDA under 21 CFR Part 1271. This is not generic stem cell product sourced from unknown suppliers. Every vial is traceable, tested, and cleared for clinical use.

Mesenchymal stem cells are multipotent, meaning they can differentiate into several cell types, including bone, cartilage, tendon, and fat tissue under the right conditions. But the primary mechanism driving their therapeutic value in clinical applications is not differentiation. It is paracrine signaling. MSCs release cytokines, growth factors, and extracellular vesicles that instruct surrounding cells to reduce inflammation, recruit repair mechanisms, and regulate immune activity at the treatment site. This signaling cascade is what gives MSC therapy its breadth of application across orthopedic, neuropathic, and systemic conditions.

All stem cell procedures at this clinic are administered under the supervision of our Medical Director, [MD_PLACEHOLDER] MD, as required by Florida SB 1768.

How Mesenchymal Stem Cells Work: The Signaling Mechanism

Umbilical cord stem cell therapy works primarily through paracrine communication, not through structural replacement of damaged cells. This is a critical distinction that separates the clinical reality of MSC therapy from popular misconceptions.

When DayZero™ MSCs are introduced into the body, either via localized injection or intravenous administration, they migrate toward areas of inflammation and injury. This homing behavior is guided by chemokine gradients, the body's chemical distress signals that draw immune and repair cells to sites of damage. MSCs follow these same gradients.

Once at the target site, MSCs execute several key functions:

Immunomodulation: MSCs suppress excessive inflammatory responses by reducing pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6, while simultaneously upregulating anti-inflammatory mediators like IL-10 and TGF-beta. In chronic inflammatory conditions, including autoimmune-adjacent arthritis, this cytokine recalibration can reduce the chronic inflammatory cycle that perpetuates tissue damage.

Trophic signaling: MSCs release growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF). These signals recruit local progenitor cells to the injury site, increase local blood vessel formation (angiogenesis), and create a biological environment more conducive to tissue repair.

Extracellular vesicle release: MSCs secrete exosomes and microvesicles carrying micro-RNA and proteins that can reprogram target cell behavior. This is a mechanism shared with exosome therapy, and in many cases MSC therapy delivers both the cells and their vesicular output simultaneously.

Direct differentiation (limited): In orthopedic applications, particularly cartilage repair, MSCs retain the capacity to contribute to tissue matrix formation under appropriate mechanical and biochemical conditions. However, relying on this mechanism as the primary driver of outcomes is not clinically supported at this time. The signaling cascade is the primary driver.

Understanding this mechanism clarifies why umbilical cord stem cell therapy is not a cure and cannot be represented as one. It is a biologic intervention that shifts the injury environment toward repair. Results depend on the severity of underlying damage, patient health status, concentration administered, and delivery method.

The transition from mechanism to clinical application leads to the question of where and how to deliver MSCs most effectively, and that begins with understanding what options exist.

Types of Stem Cell Therapy: Allogeneic vs. BMAC and Other Autologous Options

Stem cell therapy at clinical practices falls into two primary categories: allogeneic (donor-sourced) and autologous (patient-sourced). Understanding the difference is essential before making any treatment decision.

Allogeneic Umbilical Cord Stem Cells (DayZero™)

Allogeneic stem cell therapy uses MSCs derived from a donor source, in this case umbilical cord Wharton's jelly from screened, consenting donors. DayZero™ MSCs are processed at ZEO ScientifiX's AABB-accredited, ISO-7 certified cGMP facility, with FDA registration under 21 CFR Part 1271.

Advantages of allogeneic MSCs:

Cell youth: Umbilical cord MSCs are neonatal cells. They are more proliferative and express higher concentrations of growth factors than MSCs from older adult tissue.
Immediate availability: No surgical harvest required from the patient. Protocol begins with a consultation and a product selection decision.
Standardized concentration: DayZero™ vials come in confirmed concentrations, 10M and 20M cell vials for localized injections, and 100M, 120M, and 150M IV bags for systemic administration. The physician knows the exact dose being administered.
No patient harvest risk: Autologous procedures require extracting tissue from the patient, which carries anesthetic risk, procedural pain, and recovery time.

BMAC: Bone Marrow Aspirate Concentrate

Bone marrow aspirate concentrate (BMAC) is an autologous procedure where bone marrow is harvested from the patient's iliac crest, concentrated via centrifuge, and reinjected. BMAC contains MSCs, hematopoietic stem cells, and growth factors, all derived from the patient's own biology.

BMAC advantages:

No rejection risk (autologous source)
Combines MSCs with hematopoietic cells and platelets
Well-supported in orthopedic literature for cartilage, bone, and tendon applications

BMAC disadvantages:

Surgical procedure required for harvest (local anesthesia, trocar into iliac crest)
MSC yield and quality depend on patient age and health. A 65-year-old's bone marrow produces fewer and less potent MSCs than a neonatal umbilical cord.
Variable concentration, COA is not available the way it is for manufactured allogeneic product.
Higher procedural complexity, longer session time, more patient discomfort.

Adipose-Derived Stem Cells (Fat Grafting with MSCs)

A third category involves harvesting the patient's fat tissue via mini-liposuction, processing it to extract the stromal vascular fraction (SVF), which contains MSCs along with pericytes and endothelial progenitor cells. This approach is used at some clinics but is not the primary protocol at Rebuild Regen.

The Rebuild Regen Protocol: DayZero™ Allogeneic MSCs

At Rebuild Regen Medical Clinic, the standard stem cell protocol uses DayZero™ umbilical cord MSCs from ZEO ScientifiX. The choice of allogeneic sourcing over BMAC is deliberate. For the patient population at this clinic, including those with chronic orthopedic conditions, neuropathy, systemic inflammation, and age-related decline, the cell quality advantage of neonatal umbilical cord MSCs outweighs the autologous source rationale. Patients over 50 do not produce BMAC-quality MSCs equivalent to perinatal tissue.

The comparison between BMAC and DayZero™ MSCs is a conversation worth having at consultation. There is no universally correct answer. The right protocol depends on the condition, patient age, systemic health, and goals.

Conditions Addressed With Stem Cell Therapy

Umbilical cord stem cell therapy at Rebuild Regen is applied across four major clinical domains. Each represents a different mechanism of therapeutic action.

Orthopedic and Musculoskeletal Conditions

This is the most well-documented application category for MSC therapy. Conditions include:

Osteoarthritis (knee, hip, shoulder): MSC therapy targets the inflammatory cycle driving cartilage degradation. Published trials have demonstrated reductions in pain scores and improvements in joint function following intra-articular MSC injection. Longer-term cartilage preservation is an active area of research.
Tendon and ligament injuries: Partial tears of the rotator cuff, patellar tendon, Achilles tendon, and plantar fascia benefit from MSC-mediated collagen synthesis signaling. Combined protocols pairing DayZero™ MSCs with PRP or shockwave therapy are used depending on severity.
Post-surgical recovery support: Following orthopedic surgery, some patients receive IV MSC administration to accelerate the systemic inflammatory resolution phase of healing.
Degenerative disc disease: Combined with spinal decompression via the Antalgic-Trac system, MSC injection can address the inflammatory component of disc-related pain.
Avascular necrosis: MSC therapy has shown promise in early-stage avascular necrosis by stimulating angiogenesis at the affected bone.

Neuropathic Conditions

The anti-inflammatory and neurotrophic properties of MSCs make them a relevant adjunct in neuropathy treatment. DayZero™ MSC IV infusions are incorporated into the Rebuild Neuropathy Protocol for appropriate candidates, particularly those with systemic inflammatory neuropathy or small fiber neuropathy with documented nerve damage.

MSC-derived BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) support Schwann cell activity and peripheral nerve repair processes. This does not reverse established nerve death, but in patients with viable nerve tissue experiencing ongoing damage, MSC therapy can reduce the inflammatory drivers of continued degeneration.

Autoimmune-Adjacent and Systemic Inflammatory Conditions

MSCs' immunomodulatory capacity makes them relevant for chronic systemic inflammation. Conditions including rheumatoid arthritis, lupus, Crohn's disease, and multiple sclerosis have been studied in the context of MSC therapy in clinical trials. These applications are considered investigational, and the clinic positions MSC therapy as supportive rather than curative in systemic autoimmune contexts. All systemic IV protocols require full medical history review and [MD_PLACEHOLDER] MD oversight.

Age-Related and Longevity Applications

Systemic MSC IV infusions are used by some patients specifically for cellular health, anti-inflammatory burden reduction, and functional longevity goals rather than a diagnosed pathology. This is an emerging area of practice. The rationale centers on reducing systemic chronic low-grade inflammation (inflammaging), supporting mitochondrial health via paracrine signaling, and replenishing declining endogenous stem cell populations that accompany normal aging.

Who Is a Candidate for Stem Cell Therapy

Umbilical cord stem cell therapy is appropriate for a broad range of patients, but candidacy requires a clinical evaluation.

General candidacy indicators:

Diagnosed orthopedic condition, including osteoarthritis, tendinopathy, or ligament injury that has not responded adequately to conservative treatment
Neuropathy with confirmed nerve involvement and a stable systemic health picture
Systemic inflammatory condition under physician management
Age-related functional decline with goals related to mobility, pain reduction, or systemic health
Patients seeking alternatives to joint replacement surgery or corticosteroid dependency

Candidacy evaluation includes:

Comprehensive medical history
Relevant imaging (X-ray, MRI) for orthopedic applications
Lab work to assess inflammatory markers, immune status, and metabolic health
Physician consultation with [MD_PLACEHOLDER] MD for protocol design

Contraindications to stem cell therapy:

Active cancer or recent cancer history (MSC proliferative signaling could theoretically stimulate existing tumor activity)
Active infection or sepsis
Pregnancy or breastfeeding
Severe bleeding disorders or anticoagulation therapy that cannot be temporarily adjusted
Active autoimmune flare (timing matters; active flare versus stable managed disease are different clinical contexts)

The candidacy conversation is a central part of the consultation. Patients who have been declined at other clinics are encouraged to present their history. Some exclusions are absolute; others depend on clinical context and the severity and staging of the underlying condition.

What to Expect: Before, During, and After Your Procedure

Before the Procedure

The process begins with a consultation. Elizabeth Celestin, APRN, FNP-C, conducts an initial evaluation covering medical history, current symptoms, imaging and lab results, and treatment goals. For stem cell procedures, this evaluation is reviewed and co-signed by Medical Director [MD_PLACEHOLDER] MD.

Patients are given protocol-specific preparation instructions. These typically include:

Stopping anti-inflammatory medications (NSAIDs, corticosteroids) for a specified window before the procedure to avoid blunting the inflammatory signaling that MSCs rely on
Hydration and nutritional preparation guidelines
Any required pre-procedure labs

During the Procedure

The procedure varies by protocol. Local injections for orthopedic targets, including knee, shoulder, or hip, typically take 30 to 60 minutes including preparation. IV infusions run 60 to 90 minutes.

DayZero™ vial selection is determined by the treating physician based on:

Target tissue and the extent of damage
Whether the application is localized injection or systemic IV
Patient weight, age, and systemic health status

Vial options for localized injection: 10M or 20M cell vials Vial options for IV systemic administration: 100M, 120M, or 150M IV bags

All procedures take place at Rebuild Regen Medical Clinic under the direct supervision of [MD_PLACEHOLDER] MD. Elizabeth Celestin assists and monitors throughout.

Patients report minimal to moderate discomfort during injection. IV administration is generally comfortable. No general anesthesia is used.

After the Procedure

Immediate post-procedure:

Brief observation period (typically 15 to 30 minutes post-IV)
Activity restrictions vary by treatment site. Orthopedic injection patients typically restrict weight-bearing on the treated joint for 24 to 48 hours.
Anti-inflammatory restrictions continue for a defined post-procedure window (usually 48 to 72 hours)

Most patients return to normal daily activities within 24 hours of localized injections. IV protocol patients are generally without restrictions by the following day.

Follow-Up

Follow-up appointments are scheduled at 4 to 6 weeks and 3 months post-procedure. Labs and any indicated imaging are repeated to evaluate response. Protocol adjustments, including repeat administration, are determined at follow-up.

Results and Realistic Expectations

Umbilical cord stem cell therapy does not produce overnight results. The biological processes initiated by MSC administration unfold over weeks to months. Managing expectations accurately is as important as selecting the right protocol.

Typical timeline:

Week 1 to 4: The inflammatory modulation phase. Some patients report increased soreness in the first 1 to 2 weeks as immune activity reorganizes. This is expected and not a negative sign. Early responders may notice mild improvements in pain levels by week 3 to 4.
Month 1 to 3: The active repair signaling phase. Most patients report the clearest early improvement window between 4 and 12 weeks post-procedure. Reduced joint pain, improved range of motion, and decreased morning stiffness are common reports from orthopedic patients.
Month 3 to 6: The integration and consolidation phase. Cartilage and soft tissue changes that were initiated earlier become more structurally established. Patients with significant OA or neuropathy often see continued improvement through this phase.
Month 6 and beyond: For many patients, benefits plateau in the 6 to 12 month window. Some patients require a second protocol. The durability of response varies significantly based on the underlying condition, baseline severity, and patient health factors.

What influences results:

Age and baseline stem cell reserve of the patient
Severity and chronicity of the condition
Whether lifestyle factors (diet, movement, sleep) support the repair environment
Concurrent treatments, including PRP, shockwave, decompression, and nutritional support
Protocol choice: local injection versus IV, cell concentration selected

What is realistic to expect:

A significant proportion of patients with knee osteoarthritis report 50 to 70 percent reduction in pain scores at 6 months.
Neuropathy patients typically experience reduction in burning and shooting pain rather than full resolution; numbness is slower to respond.
Systemic IV protocols for inflammatory conditions typically show gradual improvements over 2 to 4 months.
No responsible provider guarantees outcomes. Results are real and documented in the literature, but individual variation is significant.

Costs: What DayZero™ Protocols Include

Stem cell therapy at Rebuild Regen Medical Clinic is priced based on the specific DayZero™ protocol selected. Cost reflects cell concentration, delivery method, and the scope of physician oversight involved.

General pricing framework:

Local injection protocols (10M or 20M vials): lower price tier, single-site application
IV systemic protocols (100M to 150M bags): higher price tier, full systemic delivery with extended physician supervision

Exact pricing is provided at consultation after the treating physician has evaluated the patient and determined the appropriate protocol. Pricing is transparent before any treatment decision is made.

What is included in the protocol fee:

Medical Director [MD_PLACEHOLDER] MD consultation and co-sign on protocol
DayZero™ product (COA-verified, AABB-accredited)
Procedure administration by Elizabeth Celestin, APRN, FNP-C under [MD_PLACEHOLDER] MD supervision
4-week and 3-month follow-up appointments
Post-procedure monitoring and protocol adjustment consultation

What is typically not included:

Pre-procedure labs (billed through standard lab services)
Pre-procedure imaging (X-ray or MRI if not already on file)
Adjunct treatments in the same visit (PRP, shockwave, IV infusions) if added to the protocol

Stem cell therapy is not covered by standard health insurance. Medical financing options are available.

The Rebuild Regen Approach: DayZero™ Sourcing, Vial Options, and Physician Oversight

The Rebuild Regen approach to stem cell therapy is defined by three elements: sourcing transparency, physician oversight, and protocol personalization.

DayZero™ Sourcing Transparency

Not all stem cell products sold in the United States meet the same quality standard. The biologics market includes products of widely varying quality, some lacking current COA documentation, some from facilities without AABB accreditation or FDA registration, and some misrepresenting cell counts.

DayZero™ umbilical cord stem cells from ZEO ScientifiX represent the upper tier of commercially available MSC product in the United States. The sourcing chain is fully documented:

Umbilical cord Wharton's jelly from consenting, full-term donors
100% non-fetal, non-embryonic (no ethical or regulatory concerns related to fetal sourcing)
Processed in an ISO-7 Clean Room at an AABB-accredited, FDA-registered cGMP facility
Every lot: COA with cell viability, sterility testing, and HLA matching data
Registered under 21 CFR Part 1271

When patients ask what product is being administered, the answer at Rebuild Regen is specific: DayZero™, lot number on request, COA available for review.

Physician Oversight Structure

Under Florida SB 1768, stem cell therapies must be administered under physician supervision. At Rebuild Regen, this is not a legal formality. Medical Director [MD_PLACEHOLDER] MD reviews every stem cell protocol, co-signs every treatment plan, and is present or immediately available during procedures. Elizabeth Celestin conducts the patient intake, prepares the patient, and monitors throughout.

This two-provider structure ensures that patients receive both the clinical warmth of a skilled nurse practitioner and the medical authority of a board-certified physician on every stem cell case.

Protocol Personalization

DayZero™ vial selection is not one-size-fits-all. The physician selects from:

10M cell vials for targeted small-joint injections or supplemental localized treatment
20M cell vials for larger joint injections or multi-site localized protocols
100M to 150M IV bags for systemic administration, whether targeting systemic inflammation, neuropathy, or longevity protocols

Protocols are also frequently combined with adjunct therapies:

PRP (platelet-rich plasma) administered at the same site to enhance local growth factor environment
Exosomes (DayZero™ exosome vials) co-administered to extend the signaling effect
IV nutritional support (NAD+, B12, ALA) for neuropathic or systemic applications
Shockwave therapy (Chattanooga Intelect RPW 2) or laser therapy (LightForce XLi) for musculoskeletal conditions requiring concurrent tissue mobilization

Regulatory Context: SB 1768 Compliance and FDA Status

FDA Status of Stem Cell Therapy

Stem cell therapy in the United States operates in a nuanced regulatory environment. The FDA does not approve most MSC products as drugs. Instead, they are regulated as human cellular and tissue products (HCT/Ps) under 21 CFR Part 1271, which governs their manufacture, testing, and distribution. Products like DayZero™ are FDA-registered under this framework.

The FDA has not approved any MSC product as a drug therapy for any specific condition. This is a different statement from saying stem cell therapy is illegal or unproven. The evidence base for MSC therapy, particularly in orthopedic and neuropathic conditions, is substantial and growing. FDA approval as a drug requires a different regulatory pathway that has not yet been completed for MSC products.

The FDA disclaimer required on this page reflects this distinction:

These stem cell therapies have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). Stem cell therapy is not intended to diagnose, treat, cure, or prevent any disease.

This disclosure is required and accurate. It does not mean stem cell therapy is experimental in a colloquial sense. It means it is regulated under the HCT/P framework rather than the drug approval framework.

Florida SB 1768

Florida Senate Bill 1768 took effect in 2023 and established specific requirements for stem cell therapy providers in Florida. Key provisions:

Stem cell procedures must be performed under the supervision of a licensed physician (MD or DO)
Providers must disclose that the procedure is not FDA-approved
Patients must receive written informed consent specific to stem cell therapy
Facilities must maintain documentation of product sourcing and quality

Rebuild Regen Medical Clinic operates in full compliance with SB 1768. [MD_PLACEHOLDER] MD serves as supervising physician on all stem cell procedures. Written informed consent including SB 1768-specific disclosures is obtained before every procedure. Product documentation including DayZero™ COAs is maintained on file.

Patients can review the full text of the law and the clinic's compliance structure at /resources/florida-stem-cell-law-sb-1768/.

Is Stem Cell Therapy Right for Your Condition?

Stem cell therapy at Rebuild Regen is not the right choice for every patient, and the consultation process is designed to answer that question honestly.

The patients most likely to benefit from umbilical cord stem cell therapy are those with:

Documented chronic inflammation driving a musculoskeletal condition
Osteoarthritis that has progressed past the point where PRP alone provides adequate response
Systemic inflammatory burden affecting multiple systems
Neuropathy with active inflammatory component
Goals related to functional longevity and cellular health

Patients for whom stem cell therapy may not be the primary recommendation include those with structural damage severe enough to require mechanical correction, acute injuries that respond well to simpler interventions, or conditions with specific contraindications identified at consultation.

The honest conversation at consultation includes the question: is there a less expensive, less invasive option that addresses this patient's specific situation first? PRP, shockwave, decompression, and hormonal correction each address some of the same conditions at lower cost and with strong evidence bases. Stem cell therapy is not always the first step. Sometimes it is the right next step after other interventions have been tried or when the clinical picture warrants starting higher.

Frequently Asked Questions

Is stem cell therapy FDA-approved?

Stem cell therapy is regulated by the FDA under 21 CFR Part 1271 as a human cellular and tissue product (HCT/P), not as an approved drug therapy. The FDA has not approved any mesenchymal stem cell product for specific disease treatment. Products like DayZero™ MSCs are FDA-registered under the HCT/P framework, which governs manufacturing standards, sterility, and donor testing. This is different from FDA drug approval. The clinic discloses this distinction fully before any procedure.

What is the difference between BMAC and umbilical cord stem cell therapy?

BMAC (bone marrow aspirate concentrate) uses the patient's own bone marrow, harvested via a minimally invasive procedure from the hip. Umbilical cord stem cell therapy uses donor-sourced MSCs from neonatal umbilical cord tissue. BMAC is autologous (same patient), which eliminates rejection risk. DayZero™ allogeneic MSCs offer the advantage of neonatal cell quality and standardized, confirmed cell concentrations. For patients over 50, the cell vitality advantage of umbilical cord MSCs is clinically meaningful. Consultation with [MD_PLACEHOLDER] MD determines which approach fits the individual case.

Who supervises stem cell procedures at Rebuild Regen?

All stem cell procedures are supervised by Medical Director [MD_PLACEHOLDER] MD in compliance with Florida SB 1768. Elizabeth Celestin, APRN, FNP-C, manages the patient experience, prepares the treatment protocol, and monitors throughout. No stem cell procedure is administered independently by a nurse practitioner at this clinic.

How many cells are in a DayZero™ treatment?

DayZero™ MSC vials are available in 10 million and 20 million cell concentrations for localized injection applications. Systemic IV protocols use 100 million, 120 million, or 150 million cell IV bags. The treating physician selects the appropriate concentration based on the condition, target site, and systemic health of the patient.

How long before I see results from stem cell therapy?

Stem cell therapy initiates a biological process that unfolds over weeks to months. Early results, typically reduced pain and improved mobility, are often reported between 4 and 12 weeks post-procedure. The most significant improvements for orthopedic patients typically occur between 3 and 6 months. Systemic and neuropathic applications may show a slower timeline depending on the severity of underlying damage.

Can stem cell therapy replace knee surgery?

Stem cell therapy is not a guaranteed alternative to joint replacement surgery. For patients with early to moderate osteoarthritis, MSC therapy can reduce pain and slow progression, in some cases delaying or avoiding the need for surgical intervention. For patients with severe joint degeneration and major structural compromise, surgery addresses mechanical issues that biologics cannot resolve. The consultation process determines whether stem cell therapy is a realistic pre-surgical alternative in a given patient's case.

How is stem cell therapy different from PRP?

Platelet-rich plasma therapy uses concentrated growth factors from the patient's own blood to stimulate local tissue repair. Stem cell therapy introduces living MSCs that actively signal, modulate inflammation, and in some contexts differentiate into target tissue. PRP is autologous and typically lower cost; stem cell therapy with DayZero™ MSCs delivers a broader signaling payload including exosomes, cytokines, and growth factors at concentrations not achievable from autologous blood. The two are frequently combined in protocols at Rebuild Regen.

Is there a risk of rejection with allogeneic stem cells?

MSCs derived from umbilical cord Wharton's jelly have low immunogenicity because they do not express the MHC II markers that trigger strong T-cell immune responses. This property is a major reason umbilical cord MSCs are used in allogeneic transplants clinically. Rejection in the traditional organ transplant sense is not observed with HCT/P-compliant MSC therapy at the dose levels used in regenerative medicine practice. Adverse immune reactions are possible and are reviewed in the informed consent process.

Can stem cell therapy be combined with other treatments?

Stem cell therapy is frequently combined with other modalities at Rebuild Regen. Common combination protocols include DayZero™ MSCs with PRP (PRP at the injection site to enhance the local growth factor environment), DayZero™ exosomes (extending the vesicular signaling component), IV nutritional infusions (NAD+, B12, ALA for systemic and neuropathic cases), and LightForce XLi laser therapy or Chattanooga Intelect RPW 2 shockwave for concurrent musculoskeletal conditions. Protocol combinations are designed at consultation based on each patient's clinical picture.

Does insurance cover stem cell therapy?

Standard health insurance does not cover stem cell therapy as it is not FDA-approved as a drug therapy. Procedures are self-pay. Rebuild Regen provides transparent pricing at consultation and financing options are available.

What makes DayZero™ different from other stem cell products?

DayZero™ umbilical cord stem cells from ZEO ScientifiX are manufactured in an AABB-accredited, FDA-registered, ISO-7 certified clean room facility. Every lot carries a Certificate of Analysis (COA) documenting cell viability, sterility, and pathogen screening. The product is 100% non-fetal and non-embryonic. Not all stem cell products sold to clinics meet this standard. Some lack current COA documentation; others are from facilities without AABB accreditation. Product sourcing is verified and documentable at Rebuild Regen.

When Stem Cell Therapy Is Not Appropriate

Umbilical cord stem cell therapy is not the right intervention for all patients or all conditions. The following circumstances represent either absolute or relative contraindications that are evaluated at consultation:

Active malignancy: MSC trophic and proliferative signaling creates a biological environment that could theoretically stimulate tumor growth. Patients with active cancer, recent cancer history, or incomplete oncology follow-up are not candidates for MSC therapy at this clinic. Oncology clearance is required before any stem cell consultation is productive.

Severe uncontrolled autoimmune disease in active flare: MSC immunomodulation can be therapeutic for stable managed autoimmune conditions, but introducing MSCs during an active systemic flare creates unpredictable immune interactions. Timing and stabilization of the underlying condition are prerequisites.

Late-stage structural joint failure: When a knee or hip has progressed to Kellgren-Lawrence Grade IV OA with severe bone-on-bone destruction, the mechanical deficit is beyond what MSC signaling can correct. Joint replacement is the structurally appropriate intervention. Stem cell therapy in this context is unlikely to deliver meaningful functional improvement and is not recommended as a substitute for surgical correction in severe cases.

Severe bleeding disorders: Injection procedures carry bleeding risk that is amplified by coagulopathies or anticoagulation therapy that cannot be appropriately paused. Protocol design in these cases requires hematology input.

Unrealistic expectations: This is not a formal contraindication, but it shapes the consultation. Patients who present expecting stem cell therapy to reverse advanced neurological disease, restore function lost to complete spinal cord injury, or act as a youth-restoration treatment without basis in clinical reality are best served by an honest conversation about what the evidence supports before any procedure is scheduled.

Patients who fall into these categories are not turned away. They are counseled on alternative interventions, appropriate referrals, and the conditions under which stem cell therapy might become an option for them.

Schedule a consultation at Rebuild Regen Medical Clinic: (954) 953-4208 | 3320 N Federal Hwy #101, Lighthouse Point, FL 33064.